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Abstract Ovarian stimulation improves assisted reproductive technology outcome by increasing the number of oocytes available for
insemination and in-vitro handling. A recent Duplex protocol features a dual stimulation, with the second stimulation started im-
mediately after the ﬁrst oocyte retrieval. Remarkably, the Duplex protocol is unexpectadly well tolerated by women and provides
twice as many oocytes and embryos as a regular antagonist protocol in less than 30 days.
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Ovarian stimulation was designed for improving assisted
reproductive technology outcome by providingmore than one
oocyte to inseminate. Logically, the ovarian stimulation pro-
tocols used in assisted reproductive technology aim tomodify
the hormonal environment of the follicular phase to fool the
natural mechanisms of single follicular dominance that nor-
mally exist inwomen.The therapeutic objectivewas to prevent
the decrease in circulating FSH occurring in themid-follicular
phase, which is precisely responsible for single follicular domi-
nance. Practically, this is achieved by enhancing the endog-
enous productionof FSH, using clomiphenecitrate or aromatase
inhibitors, or by providing exogenous FSH and human meno-
pausal gonadtotrophin. Today, 3 decades later, ovarian stimu-
lation remains the single most effective measure ever taken
for improving assisted reproductive technology outcome.
The time constraints associated with emergency fertility
preservation before starting oncology treatments has led to
shorter ovarian stimulation protocols being used. This was
notably achieved by starting stimulation at any time in the
menstrual cycle (the ‘random-start’ protocols) rather than pre-
cisely in the early follicular phase or after down regulation
(Ozkaya et al., 2012). The ‘freeze all’ design used in fertil-
ity preservation treatments therefore no longer required
ovarian stimulation to be dependent on the physiological ad-
vancement of the endometrium to optimize the chances of
embryo implantation.
The only unknown was whether the random start of stimu-
lation might alter the size of the oocyte crop, its function-
ality (fertilization rates), or both. These fears were rapidly
dismissed, as the oocyte yields of the ‘random-start’
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protocols were found to equal those of ovarian stimulation
started in the early follicular phase (Cakmak et al., 2013).
These data indicate that ovarian stimulation can be totally
disconnected from the cycling phases of endogenous gonado-
trophins without any detrimental consequences, as long as
no fresh embryo transfer takes place.
In parallel with the new challenges encountered in fertil-
ity preservation, cryopreservation has made a quantic leap
forward through the improvement of oocyte and embryo vit-
riﬁcation. Oocyte and embryo vitriﬁcation indeed offered
access to an emerging new realm of ‘no-loss cryopreservation’,
which brings to the fore a multitude of new practical options
in assisted reproductive technology.
Moreover, the achievements of oocyte and embryo vitri-
ﬁcation dovetailed perfectly with a novel mode of trigger-
ing ﬁnal stage of oocyte maturation. Indeed, the advent of
antagonist stimulation protocols revived the possibility of trig-
gering ovulation with gonadotrophin-releasing hormone (GnRH)
agonist that induces an endogenous surge of LH and FSH
(Gonen et al., 1990; Itskovitz et al., 1991), instead of using
exogenous HCG (5–10,000 IU). This approach described over
2 decades ago could not be used when gonadotrophin down-
regulation GnRH agonist protocols were the rule in assisted
reproductive technology. The ‘GnRH-trigger’ option is widely
used in oocyte donors (Bodri et al., 2010; Weissman et al.,
2014) and for avoiding the risk of ovarian hyperstimulation
syndrome (OHSS) in association with a freeze-all strategy
(Weissman et al., 2014).
Kuang et al., (2014a) capitalized on the combined achieve-
ments of the random-start protocols and embryo vitriﬁca-
tion by testing the possibility of deliberately starting ovarian
stimulation during the luteal phase. The investigators showed
that ‘luteal-phase start’ stimulation is feasible, and pro-
duces a normal number of competent oocytes and optimal
pregnancy rates from cryopreserved embryo transfer cycles.
In their trial, ovarian stimulation was accomplished using a
combination of aromatase inhibitor (letrozole 2.5 mg/day) and
human menopausal gonadotrophin (225 IU/day), starting im-
mediately after spontaneous ovulation until three or more fol-
licles had reached a diameter of 18 mm or wider. Final oocyte
maturation was triggered using triptorelin 0.1 mg. All 242 par-
ticipants underwent oocyte retrieval, which yielded 13.1
oocytes on average and achieved a clinical pregnancy rate in
cryopreserved embryo transfer cycles of 48.9%. Logically,
Kuang’s (Kuang et al., 2014a) data further fuelled the concept
that ovarian stimulation can be dissociated from the follicu-
lar phase and its hormonal environment, as long as no fresh
embryo transfer takes place.
In this issue of Reproductive Medicine Online, the same
team of investigators recount their experience, venturing one
step further by adapting ovarian stimulation to the needs of
certain groups of patients (Kuang et al., 2014b). In their
current study, Kuang et al. (2014b) conducted two succes-
sive ovarian stimulations in the follicular and ensuing luteal
phase. The trial was conducted in 38 patients who all ful-
ﬁlled the Bologna criteria for poor responders, based on prior
ovarian stimulation outcome, baseline hormonal levels and
age. The ﬁrst and second stimulations used two different regi-
mens as follows: the ﬁrst stimulation was conducted using a
combination of clomiphene citrate 25 mg per day starting on
day 3 of the cycle until the triggering of ovulation; letrozole
2.5 mg per day starting on day 3, for a total of 4 days; and
humanmenopausal gonadotrohin 150 IU every other day, start-
ing on day 6 until the triggering of ovulation. The second stimu-
lation was started after the ﬁrst oocyte retrieval, provided
that two or more antral follicles were identiﬁed. This stimu-
lation regimen, which differed from the ﬁrst stimulation,
consisted of letrozole 2.5 mg and human menopausal gonado-
trophin (225 IU/day), which were both started from the day
of retrieval until the second triggering of ovulation.
For both the ﬁrst and second stimulations, ﬁnal oocyte
maturation was induced with triptorelin 0.1 mg adminis-
tered when three or more follicles measured 18 mm or more
in diameter. Furthermore, premature ovulation was pre-
vented using ibuprofen (600 mg/day) on the day of trigger-
ing ovulation and the day after. Notably, no GnRH antagonist
was used in either stimulation. Ultimately, 30 out of of 38 pa-
tients underwent two consecutive oocyte retrievals, with the
second ovarian stimulation yielding a larger number of oocytes
and embryos than the ﬁrst.
The magnitude of the ovarian response of the ﬁrst and
second ovarian stimulation cannot be directly compared in
Kuang’s data because of the marked difference in the stimu-
lation regimens used in each of them. It remains, however,
that Kuang’s study (2014b) provides clear evidence that a
second ovarian stimulation can be conducted immediately
after a ﬁrst stimulation and oocyte retrieval, leading to a valu-
able improvement in the overall number of oocytes and
embryos obtained.
Kuang et al. presented their data on luteal phase stimu-
lation presented at the ﬁfth Asia Paciﬁc Congress on Build-
ing Consensus out of Controversies in Gynecology and
Infertility, November 21–24, 2013. A year later, the same group
presented the double stimulation at the Controversies in Gy-
necology and Infertility meeting in Barcelona (COG–IMSRM April
25–26, 2014). Following on from these ﬁndings, we similarly
offered a dual stimulation, the ‘Duplex protocol’ (DPX), to
patients whose response to ovarian stimulation was bound to
be weak. We feel that it is appropriate to provide some of
our preliminary data here, as a conventional dual FSH-
antagonist ovarian stimulation approach was used in our DPX
protocol. Hence, our data expand the interest for the dual
ovarian stimulation strategy, indicating that it is not limited
to the speciﬁc protocol but rather complex protocol used by
Kuang et al. (2014b). Our preliminary data tend to conﬁrm
Kuang’s ﬁndings. In our study, a second ovarian stimulation
started immediately after a ﬁrst oocyte retrieval was well tol-
erated and provided as many oocytes and blastocysts, as ob-
tained in the ﬁrst ovarian stimulation. In our DPX protocol,
both the ﬁrst and second stimulations used a similar regimen
consisting of a classical antagonist protocol using 300 IU of
FSH per day, cetrorelix 0.25 mg starting on ovarian stimula-
tion day 6 and GnRH trigger (triptorelin 0.2 mg) when fol-
licular maturation was reached. The ﬁrst and second
stimulations provided a similar number of oocytes, zygotes
and blastocysts. The DPX protocol thus doubled the ﬁnal blas-
tocyst yield, compared with a classical single-ovarian stimu-
lation assisted reproductive technology cycle. Data from our
DPX protocol that used conventional ovarian stimulation regi-
mens, identical for the ﬁrst and second stimulations, support
the ﬁndings of Kuang’s report published in this issue of Re-
productive Medicine Online (Kuang et al., 2014b). A striking
ﬁnding in our DPX experience, also reported by Kuang, is the
good general tolerance of the second ovarian stimulation
660 R Moffat et al.
started immediately after a ﬁrst oocyte retrieval. No cyst,
undue pain, or both, were encountered by any of our DPX
participants.
Kuang’s data (2014b) and our ﬁndings indicate that a dual
back-to-back ovarian stimulation protocol is a viable option
for coping with the insufﬁcient ovarian responses that are
sometimes encountered in ART. Moreover, the short overall
duration of these approaches (<30 days) is valuable for cases
of fertility preservation. Indeed, the DPX approach permits
coping with the time constraints of fertility preservation and
the desire to accumulate the largest number of oocytes
possible.
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